Mepolizumab: a new drug programme for patients with severe eosinophilic asthma
Journal Title: JOURNAL OF HEALTH POLICY & OUTCOMES RESEARCH - Year 2017, Vol 2, Issue 2
Abstract
Biological treatment involves more and more fields of medicine. This also applies to severe asthma for which a therapy with omalizumab (anti-IgE antibodies for patients with allergic asthma) has been available since 2013, completed by mepolizumab since 1st November 2017 - available in a new drug programme. Mepolizumab is a humanised monoclonal antibody (IgG1, κ), against human interleukin-5 (IL-5), which significantly impacts proliferation, maturation in bone marrow and recruitment and activation of eosiniphils at inflammatory site. It is also considered to be the only eosinophilopoietic factor. It has been confirmed in a number of studies that mepolizumab, used by patients suffering from eosinophillic asthma, decreases the number of exacerbations and reduces systemic glucocorticoid doses. The approval of mepolizumab therapy to trading in Poland is regulated by provisions of the drug programme, discussed in detail further in this paper.
Authors and Affiliations
Aleksandra Kucharczyk, Piotr Materla
Keywords
Related Articles
- EP ID EP326197
- DOI 10.7365/JHPOR.2017.2.4
- Views 83
- Downloads 0
What should we know about the Zika virus?
Zika virus (ZIKV) is a vector-borne arbovirus of the Flaviviridae family, which also includes dengue, West Nile, yellow fever and Japanese encephalitis viruses. It is transmitted by daytime-active Aedes mosquitoes. Simi...
Severe allergic asthma treatment in Poland
Severe asthma is a heterogeneous disease, which, as it is now believed, requires a personalized therapy dependent on phenotype. Omalizumab, a humanized monoclonal antibody that specifically binds to free immunoglobulin E...
The study of the need for interprofessional collaboration in the health care system in Poland - experience of Lesław A. Paga Foundation.
Background: Interprofessional collaboration (IC) in healthcare is a process by which professionals from different disciplines collaborate to provide an integrated and cohesive approach to patient care. The Lesław A. Paga...
Treatment and prevention of bleeding in adult hemophilia A patients with inhibitor – economic analysis.
Hemophilia A is caused by an absence or deficiency of coagulation factor VIII. Patients with hemophilia may experience recurrent spontaneous hemarthroses or internal bleeding. Following the treatment with factor VIII con...
Pharmaceutical system in Ukraine: current and prospective issues
ntroduction: To review the current pharmaceutical system in the private and public sectors in Ukraine in terms of the availability and affordability of medicines, to explore and analyze national health system reforms sta...